HAVCR2 and breast cancer: Notably, a high expression of TIM-3 on the murine equivalent of human cDC1s has been recently described (64), and an important role of TIM-3 expression on these cells has been suggested by the observation that, in a murine model of breast cancer, treatment with TIM-3-blocking antibody increased the immune-mediated response to therapy through cDC1-dependent, not yet clarified mechanisms (64).